Pfizer stock: FDA expands Tukysa’s breast cancer approval
October 7, 2026
Pfizer gained a new U.S. approval for Tukysa on October 7, opening an earlier maintenance-treatment setting for the breast-cancer medicine. The FDA decision covers tucatinib with trastuzumab and pertuzumab for adults with unresectable locally advanced…
